Rhabdomyosarcoma Clinical Trial
Official title:
A Phase I/II Dose Escalation/Dose Expansion Study of Prexasertib in Combination With Irinotecan in Patients With Relapsed or RefractoryDesmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Verified date | October 2023 |
Source | Memorial Sloan Kettering Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test whether the study drug prexasertib is a safe and effective treatment for people with DSRCT or RMS when given in combination with the standard drugs irinotecan and temozolomide. The study will test different doses of prexasertib in combination with irinotecan and temozolomide to find the highest dose of prexasertib that causes few or mild side effects in participants.
Status | Active, not recruiting |
Enrollment | 21 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Months and older |
Eligibility | Inclusion Criteria: - Consent/Assent: all patients and/or their parents or legally authorized representatives must sign written informed consent; assent, when appropriate, will be obtained according to institutional guidelines - Age: patients must be =12 months of age at the time of study enrollment - Diagnosis: patients must have histologically documented locally advanced or metastatic desmoplastic small round cell tumor or rhabdomyosarcoma (confirmed at MSK) - Therapeutic options: patient's current disease state must be one which has failed standard therapy and for which there is no known curative therapy - Disease Status: patients must have measurable disease based on RECIST 1.1 - Performance level: Karnofsky = 50% for patients > 16 years of age and Lansky = 50 for patients = 16 years of age - Prior Therapy: patients may have had any number of prior therapies, but must have recovered from the acute toxic effects of all prior anti-cancer therapy (other than alopecia) as described below and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment °patients who have previously received irinotecan and/or temozolomide will be allowed - 21 days must have elapsed after the last dose of cytotoxic or myelosuppressive chemotherapy - 7 days must have elapsed after the last dose of anti-cancer agents not known to be myelosuppressive - 14 days must have elapsed after radiation therapy, and toxicity related to prior radiation therapy must be recovered to grade = 1 - 21 days must have elapsed after the last dose of antibody therapy, and toxicity related to prior antibody therapy must be recovered to grade = 1 - Organ Function Requirements: Adequate bone marrow function defined as: - absolute neutrophil count (ANC) = 1500/mm^3 - platelet count = 100,000/ mm^3 - hemoglobin = 8 g/dl - Adequate renal function defined as: - Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min/1.73m2 OR - Serum creatinine based on age/gender derived from the Schwartz formula for estimating GFR53 - Adequate liver function defined as: - Bilirubin (sum of conjugated + unconjugated) = 1.5 x upper limit of normal for age - AST or ALT = 5 x upper limit of normal for patients with liver metastases - Serum albumin = 2.5 g/dl - Adequate cardiac function defined as: - echocardiogram with left ventricular ejection fraction (LVEF) >45% - QTc < 470 ms on screening 12 lead electrocardiogram - Pregnancy/Contraception - post-menarchal females must have a negative urine or serum pregnancy test at screening and = 24 hours prior to study treatment - males or females of reproductive potential must be willing to use a barrier method of contraception throughout the course of the study and for 6 months after participation Exclusion Criteria: - Patients for whom the investigator deems that irinotecan and temozolomide are not appropriate are not eligible. - Patients who have an uncontrolled infection are not eligible. - Patients who are pregnant or breast feeding are not eligible. - Patients who have a history of Torsades de Pointes, carry a diagnosis of congestive heart failure, or have a family history of prolonged QT syndrome are not eligible. - Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible. - Patients with known hypersensitivity to irinotecan or its excipients are not eligible. |
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | recommended phase II does of Prexasertib | The RP2D is defined as the highest dose level associated with not more than 1 DLT out of 6 patients. A total of 5 dose levels are planned, including 2 back up levels. The DLT's will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The dose escalation will follow a 3+3 design. | 1 year | |
Primary | response | will be evaluated in this study using the criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline, version 1.1 (Primary response criteria)54. Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04388839 -
Evolutionary Therapy for Rhabdomyosarcoma
|
Phase 2 | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
Completed |
NCT00520936 -
A Study of Pemetrexed in Children With Recurrent Cancer
|
Phase 2 | |
Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT06094101 -
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04625907 -
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT01661400 -
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04337177 -
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02945800 -
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06029465 -
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
|
||
Terminated |
NCT02536183 -
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00592592 -
Proton RT for the Treatment of Pediatric Rhabdomyosarcoma
|
Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT01505569 -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
|
N/A | |
Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT05093322 -
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04956198 -
Drug Sensitivity and Mutation Profiling
|
||
Recruiting |
NCT04791228 -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03709680 -
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
|
Phase 1/Phase 2 |